Browsing tag:

sitagliptin


The recent announcement from actor Tom Hanks revealing his diagnosis of Type 2 diabetes was stunning for Hollywood and his numerous fans. How could Tom, an in shape and active actor have this dreadful diagnosis? Endocrinologists believe a variety of factors contributed to Tom Hanks diabetes – particularly his type 2 status, including likely genetic components, weight[…]

Read More

An FDA Advisory Committee recommended the approval of Canagliflozin, CAS# 842133-18-0, for the treatment of type 2 diabetes. The approval in January 2013 was an encouraging move for Johnson and Johnson, who will market Canagliflozin as the brand Invokana. As an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least[…]

Read More

Cases of Diabetes, particularly type 2 Diabetes have skyrocketed worldwide and in the United States. According to the National Diabetes Information Clearinghouse Diabetes affects 25.8 million people of all ages, or roughly 8.3 percent of the U.S. population. The majority of these cases in the United States, upwards of 90 percent, are of the type[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service